Business
Tonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience
CHATHAM, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"CHATHAM, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced a poster presentation by an academic collaborator at Neuroscience 2022 by the Society for Neuroscience being held November 12-16, 2022, at the San Diego Convention Center in San Diego, Calif. Poster Presentation Details: Title:In Vitro Impact of Oxytocin on Human Sensory NeuronsSession:Poster Session IDate:November 14, 2022Time:1:00 p.m. – 2:00 p.m. PTAuthors: David C. Yeomans, Ph.D., Associate Professor, Anesthesiology, Perioperative and Pain Medicine, Stanford University and David Hsu, Ph.D., Senior Scientist, Tonix PharmaceuticalsPresenter:David C. Yeomans, Ph.D., Associate Professor, Anesthesiology, Perioperative and Pain Medicine, Stanford University A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Tonix Pharmaceuticals Holding Corp.* Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the second quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the fourth quarter of ...